Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:receptor_tyrosine_kinase
gptkb:drug |
| gptkbp:administeredBy |
oral
|
| gptkbp:approvedBy |
gptkb:FDA
2020 |
| gptkbp:ATCCode |
L01EX19
|
| gptkbp:brand |
Qinlock
|
| gptkbp:CASNumber |
1065146-93-6
|
| gptkbp:chemicalFormula |
C26H27F6N5O3
|
| gptkbp:developedBy |
Deciphera Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
ripretinib
|
| gptkbp:indication |
GIST after prior kinase inhibitor therapy
advanced gastrointestinal stromal tumor |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits mutant KIT and PDGFRA kinases
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL3989989
71288861 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
abdominal pain constipation fatigue alopecia myalgia |
| gptkbp:target |
gptkb:PDGFRA
gptkb:KIT |
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:usedFor |
gptkb:gastrointestinal_stromal_tumor
|
| gptkbp:bfsParent |
gptkb:gastrointestinal_stromal_tumor
|
| gptkbp:bfsLayer |
7
|